Steven Glazer

Steven Glazer is a Partner at Ventac Partners and holds concurrent executive roles as Medical Director at RhoVac AB and Chief Medical Officer at Idogen AB. With over 30 years of international life sciences experience, he previously served as Director of Haematology at Novo Nordisk AS and Vice President of Development at Zealand Pharma. Glazer also held senior leadership positions including Senior Vice President of Development at Bioinvent International AB and Chief Medical Officer at Hansa Medical AB. He earned his Doctor of Medicine degree from the University of Copenhagen and specializes in navigating FDA and EMA regulatory processes for clinical phase 1 and phase 2 proof-of-concept studies. His current focus centers on advancing clinical development, executing drug licensing deals, and driving regulatory strategies across oncology, immunology, and haematology therapeutics from pre-clinical stages through commercialization.